Access & Reimbursement Support

This information is provided for educational purposes only. Bristol Myers Squibb cannot guarantee insurance coverage or reimbursement. Coverage and reimbursement may vary significantly by payer, plan, patient, and setting of care and is subject to frequent change. It is the sole responsibility of the healthcare provider to select the proper codes and ensure the accuracy of all statements used in seeking coverage and reimbursement for an individual patient.

Claim Submission by Treatment Center

General coding and billing considerations for Bristol Myers Squibb CAR T cell therapies

Coding and billing for CAR T cell therapies will vary based on the patient’s condition, provided services, payer-specific requirements, and selected site/setting of care. It is critical for treatment centers to confirm specific payer requirements prior to claim submission in order to avoid processing delays or denials.

Unique Coding Dynamics

HCPCS, Level II Codes	Q-codes have been assigned to previously approved CAR T cell therapies; their descriptions include leukapheresis and dose preparation procedures¹ Newly approved biologics, including CAR T cell therapies, will not initially have unique HCPCS codes; miscellaneous HCPCS codes may be reported until a unique HCPCS code is assigned by CMS
Hospital Revenue Codes	CAR T cell therapy–specific revenue codes became effective in 2019² Payer requirements for inpatient/outpatient hospital facilities may vary
ICD-10-PCS Codes	CAR T cell therapy–specific ICD-10-PCS codes became effective in 2017³ Starting in 2020, CMS assigned unique ICD-10-PCS codes for each CAR T cell therapy product³ CAR T cell therapy–specific ICD-10-PCS codes were updated, effective October 1, 2021³ Payer requirements for inpatient hospital facilities may vary
CPT^® Codes*	CAR T cell therapy–specific CPT Category III codes became effective in 2019^1,2 CMS requires physicians and providers to bill these CAR T cell therapy–specific CPT Category III codes²; private payer policies may vary CPT Category III codes generally do not have assigned relative value units and may not be payable⁴

Coding & Billing Requirements by Payer Segment

Medicare Fee-for-Service (FFS)

Billing instructions have been issued by CMS
- For more information, visit Medicare Transmittal 10891 and Medicare Transmittal 11179^5,6

Medicare Advantage (MA) Plans

Starting in January 2021, CAR T cell therapy is paid by MA plans

Billing requirements may vary by payer

Commercial Plans and Other Payers

Billing requirements may vary by payer

Visit the Resource Library for informative downloadable tools.

CMS=Centers for Medicare and Medicaid Services; CPT=Current Procedural Terminology; FARS/HHSARS=financial assistance reporting system/health and human services acquisition regulations; HCPCS=Healthcare Common Procedure Coding System; ICD-10-PCS=International Classification of Diseases, Tenth Revision, Procedure Coding System.

Downloadable resource

CAR T cell therapy claim submission checklist

Product-Specific Resources

For product-specific resources, click here.

CAR=chimeric antigen receptor.

This information is provided for educational purposes only. Bristol Myers Squibb cannot guarantee insurance coverage or reimbursement. Coverage and reimbursement may vary significantly by payer, plan, patient, and setting of care and may be subject to frequent change. It is the sole responsibility of the healthcare provider to select the proper codes and ensure the accuracy of all statements used in seeking coverage and reimbursement for an individual patient.

References

CMS. Fed Regist. November 16, 2021:86(218):63458-63998.
CMS. Chimeric antigen receptor (CAR) T-cell therapy revenue code and HCPCS setup revisions. MLN Matters SE19009. https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/Downloads/SE19009.pdf. Accessed April 26, 2022.
CMS. Fed Regist. August 13, 2021. IPPS FY 2022 Final Rules. 2021;86(154):44774-45615.
AMA. CPT Category III Codes. https://www.ama-assn.org/system/files/cpt-category3-codes-long-descriptors.pdf. Accessed April 26, 2022.
CMS. Transmittal 10891; July 20, 2021. https://www.cms.gov/files/document/r10891cp.pdf. Accessed April 26, 2022.
CMS. Transmittal 11179, January 12, 2022. https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/Transmittals/r11179otn. Accessed April 26, 2022.

You are now entering the Cell Therapy 360^® Scheduling and Apheresis Portal.

Continue

Stay on CellTherapy360.com

The Bristol Myers Squibb insurance coverage site is coming soon.

Stay on CellTherapy360.com

You are about to leave this Bristol-Myers Squibb Company site. You are being redirected to another Bristol-Myers Squibb Company site.

Continue

Stay on CellTherapy360.com

You are now leaving this Bristol Myers Squibb site.

This internet site may provide links or references to other sites. BMS has no responsibility for the content of such other sites and is not liable for any damages or injury arising from that content. Any links to other sites are provided merely as a convenience to the users of this internet site.

Continue

Stay on CellTherapy360.com

Are you sure you want to leave the enrollment section?

Your work will not be saved until you fill out the Patient Authorization and Consent page and submit your part of the enrollment form.

Finish enrollment

It won’t take long!

Exit enrollment and lose my work

You are about to leave this Bristol-Myers Squibb Company site. You are being redirected to another Bristol-Myers Squibb Company site.

Please confirm your patient’s diagnosis:

R/R large B-cell lymphoma (R/R LBCL)
R/R=relapsed/refractory.

Stay on CellTherapy360.com

Please confirm that you are a: